SCOPUS 정보 검색 플랫폼

Volumn 86, Issue 9, 2002, Pages 1367-1372

Randomised, phase ii trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

(12) Talbot, D C a Moiseyenko, V b Van Belle, S c O'reilly S M d Alba Conejo, E e Ackland, S f Eisenberg, P g Melnychuk, D h Pienkowski, T i Burger, H U j Laws, S k Osterwalder, B j

a CHURCHILL HOSPITAL (United Kingdom)

b N N PETROV RESEARCH INSTITUTE OF ONCOLOGY (Russian Federation)

c GHENT UNIVERSITY HOSPITAL (Belgium)

d CLATTERBRIDGE CENTRE FOR ONCOLOGY (United Kingdom)

e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA (Spain)

f NEWCASTLE MATER HOSPITAL (Australia)

g Marin Oncology Associates (United States)

h MCGILL UNIVERSITY (Canada)

i INSTITUTE OF ONCOLOGY (Poland)

more..

Author keywords

Anthracycline resistant; Breast cancer; Capecitabine; Fluoropyrimidine; Paclitaxel

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TREATMENT OUTCOME;

EID: 18444417397 PISSN: 00070920 EISSN: None Source Type: Journal
DOI: 10.1038/sj.bjc.6600261 Document Type: Article

Times cited : (184)

References (31)

1
- 0003267120
- First-line capecitabine treatment for metastatic breast cancer (MBC): Updated data from a randomised phase II trial
- Paris (abstract S4-10)
- (2000) Proceedings from 10th International Congress on Anti-Cancer Treatment
- Aapro, M.¹

2
- 0030757461
- Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990
- (1997) Eur J Cancer , vol.33 , pp. 1075-1107
- Black, R.J.¹ Bray, F.² Ferlay, J.³ Parkin, D.M.⁴

3
- 0032795880
- Xeloda® in the treatment of metastatic breast cancer
- (1999) Oncology , vol.57 , pp. 16-20
- Blum, J.L.¹

4
- 0033050165
- Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
- (1999) J Clin Oncol , vol.17 , pp. 485-493
- Blum, J.L.¹ Jones, S.E.² Buzdar, A.U.³ LoRusso, P.M.⁴ Kuter, I.⁵ Vogel, C.⁶ Osterwalder, B.⁷ Burger, H.U.⁸ Brown, C.S.⁹ Griffin, T.¹⁰

5
- 0000624143
- A multicenter phase II study of Xeloda™ (capecitabine) in taxane-refractory metastatic breast cancer
- abstract 403
- (1999) Proc Am Soc Clin Oncol , vol.18 , pp. 107a
- Blum, J.L.¹ Buzdar, A.U.² Dieras, V.³ LoRusso, P.M.⁴ Rutman, O.⁵ Curtiss, K.⁶ Thibault, A.⁷ Griffin, T.⁸

6
- 0032829692
- Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patients: The French compassionate use programme experience
- (1999) Eur J Cancer , vol.35 , pp. 1431-1439
- Bonneterre, J.¹ Spielman, M.² Guastalla, J.-P.³ Marty, M.⁴ Viens, P.⁵ Chollet, P.⁶ Roché, H.⁷ Fumoleau, P.⁸ Mauriac, L.⁹ Bourgeois, H.¹⁰ Namer, M.¹¹ Bergerat, J.P.¹² Misset, J.-L.¹³ Trandafir, L.¹⁴ Mahjoubi, M.¹⁵

7
- 0000078840
- A randomized crossover trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer
- abstract 741
- (2000) Proc Am Soc Clin Oncol , vol.19 , pp. 191a
- Borner, M.¹ Schöffski, P.² De Wit, R.³ Caponigro, F.⁴ Comella, G.⁵ Sulkes, A.⁶ Peters, G.⁷ Grÿnwald, V.⁸ Wanders, J.⁹ De Boer, R.¹⁰ Martin, C.¹¹ Fumoleau, P.¹²

8
- 0000092361
- Antitumor efficacy of capecitabine against fluorouracil-sensitive and resistant tumors
- abstract 795
- (1997) Proc Am Soc Clin Oncol , vol.16 , pp. 226a
- Cao, S.¹ Lu, K.² Ishitsuka, H.³ Rustum, Y.M.⁴

9
- 0001634968
- Thymidine phosphorylase expression in colorectal tumors together with that of thymidylate synthase predict tumor response to 5-fluorouracil
- abstract 4127
- (1997) Proc Am Assoc Cancer Res Annu Meet , vol.38 , pp. 614-615
- Danenberg, K.¹ Metzger, R.² Salonga, D.³ Lenz, H.-J.⁴ Leichman, L.⁵ Leichman, G.⁶ Baranda, J.⁷ Schwarz, E.-L.⁸ Adler, S.⁹ Danenberg, P.V.¹⁰

10
- 0028243370
- Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer
- (1994) Ann Oncol , vol.5 , pp. 423-426
- Degardin, M.¹ Bonneterre, J.² Hecquet, B.³ Pion, J.M.⁴ Adenis, A.⁵ Horner, D.⁶ Demaille, A.⁷

11
- 0029801804
- Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - A phase II study
- (1996) Cancer Chemother Pharmacol , vol.39 , pp. 150-156
- Fazeny, B.¹ Zifko, U.² Meryn, S.³ Huber, H.⁴ Grisold, W.⁵ Dittrich, C.⁶

12
- 0032414730
- Capecitabine - A novel oral tumor-activated fluoropyrimidine
- (1998) Onkologie , vol.21 , pp. 451-458
- Frings, S.¹

13
- 0027942353
- The taxoids: Paclitaxel and docetaxel
- (1994) Lancet , vol.344 , pp. 1267-1272
- Gelmon, K.¹

14
- 0032887664
- Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
- (1999) J Clin Oncol , vol.17 , pp. 3038-3047
- Gelmon, K.¹ Eisenhauer, E.² Bryce, C.³ Tolcher, A.⁴ Mayer, L.⁵ Tomlinson, E.⁶ Zee, B.⁷ Blackstein, M.⁸ Tomiak, E.⁹ Yau, J.¹⁰ Batist, G.¹¹ Fisher, B.¹² Iglesias, J.¹³

15
- 0002500431
- Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
- (2000) Ann Oncol , vol.11 , pp. 60
- Hoff, P.M.¹

16
- 0032189117
- Treatment of breast cancer
- (1998) N Engl J Med , vol.339 , pp. 974-983
- Hortobagyi, G.N.¹

17
- 0033215061
- Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma
- (1999) Cancer , vol.86 , pp. 1251-1257
- Ibrahim, N.K.¹ Rahman, Z.² Valero, V.³ Willey, J.⁴ Theriault, R.L.⁵ Buzdar, A.U.⁶ Murray, I.L.⁷ Bast, R.⁸ Hortobagyi, G.N.⁹

18
- 0033006836
- Cancer statistics 1999
- (1999) Ca Cancer J Clin , vol.49 , pp. 8-31
- Landis, S.H.¹ Murray, T.² Bolden, S.³ Wingo, P.A.⁴

19
- 0006150731
- Breast cancer
- Fauci AS, Braunwald E, Isselbacher KJ (eds), New York: McGraw-Hill
- (1998) Harrison's Principles of Internal Medicine , pp. 562-568
- Lippman, M.E.¹

20
- 0031017851
- Patient preferences for oral versus intravenous palliative chemotherapy
- (1997) J Clin Oncol , vol.15 , pp. 110-115
- Liu, G.¹ Franssen, E.² Fitch, M.I.³ Warner, E.⁴

21
- 0032772142
- Optimizing chemotherapy for patients with advanced breast cancer
- (1999) Int J Cancer Res Treat , vol.57 , pp. 21-26
- Marty, M.¹ Espie, M.² Cottu, P.H.³ Cuvier, C.⁴ Lerebours, F.⁵

22
- 0032127244
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
- (1998) Eur J Cancer , vol.34 , pp. 1274-1281
- Miwa, M.¹ Ura, M.² Nishida, M.³ Sawada, N.⁴ Ishikawa, T.⁵ Mori, K.⁶ Shimma, N.⁷ Umeda, I.⁸ Ishitsuka, H.⁹

23
- 0000709431
- A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first-line chemotherapy of breast cancer in women aged ≥ 55 years
- abstract 398
- (1998) Proc Am Soc Clin Oncol , vol.12 , pp. 103a
- O'Shaughnessy, J.A.¹ Moiseyenko, V.² Bell, D.³ Nabholz, J.M.⁴ Miles, D.⁵ Gorbunova, S.⁶ Laws, S.⁷ Griffin, T.⁸ Osterwalder, B.⁹

24
- 0000396108
- A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine)
- abstract 400
- (2000) Proc Am Soc Clin Oncol , vol.19 , pp. 104a
- O'Shaughnessy, J.¹ Blum, J.²

25
- 0002428487
- Antineoplastics and immunosuppressants
- London: The Pharmaceutical Press
- (1999) Martindale The Complete Drug Reference , pp. 470-572
- Parfitt, K.¹

26
- 0032437869
- Paclitaxel in breast cancer
- (1998) Oncologist , vol.3 , pp. 373-389
- Perez, E.A.¹

27
- 0034016415
- Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients
- (2000) Cancer Chemother Pharmacol , vol.45 , pp. 291-297
- Schüller, J.¹ Cassidy, J.² Dumont, E.³ Roos, B.⁴ Durston, S.⁵ Banken, L.⁶ Utoh, M.⁷ Mori, K.⁸ Weidekamm, E.⁹ Reigner, B.¹⁰

28
- 0001570775
- Selective effect of adjuvant 5′-deoxy-5-fluorouridine treatment for thymidine phosphorylase positive tumors in primary breast cancer
- abstract 481
- (1997) Proc Am Soc Clin Oncol , vol.16 , pp. 136a
- Toi, M.¹ Ohashi, T.² Takatsuka, Y.³ Shin, E.⁴ Inaji, H.⁵ Yamamoto, Y.⁶ Tominaga, T.⁷

29
- 0033010030
- Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer
- (1999) Semin Oncol , vol.26 , pp. 21-26
- Trudeau, M.E.¹

30
- 0034016343
- Capecitabine (Xeloda™), an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
- (2000) J Clin Oncol , vol.18 , pp. 1337-1345
- Van Cutsem, E.¹ Findlay, M.² Osterwalder, B.³ Kocha, W.⁴ Dalley, D.⁵ Pazdur, R.⁶ Cassidy, J.⁷ Dirix, L.⁸ Twelves, C.⁹ Allman, D.¹⁰ Seitz, J.-F.¹¹ Schölmerich, J.¹² Burger, H.U.¹³ Verweij, J.¹⁴

31
- 0003486933
- WHO, Geneva, publication No. 48
- (1979) Handbook for reporting results of cancer treatment

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.